Evidence map›Paper›PMID 40362171›Full record

ReviewInternational journal of molecular sciences2025

Role of the Intestinal Microbiota in the Molecular Pathogenesis of Atypical Parkinsonian Syndromes.

Dominika Przewodowska, Piotr Alster, Natalia Madetko-Alster

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Dominika PrzewodowskaDepartment of Neurology, Medical University of Warsaw, Kondratowicza 8, 03-242 Warsaw, Poland.
Piotr AlsterDepartment of Neurology, Medical University of Warsaw, Kondratowicza 8, 03-242 Warsaw, Poland.ORCID 0000-0002-5371-6817
Natalia Madetko-AlsterDepartment of Neurology, Medical University of Warsaw, Kondratowicza 8, 03-242 Warsaw, Poland.ORCID 0000-0001-8685-475X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The role of the intestinal microbiota and its influence on neurodegenerative disorders has recently been extensively explored, especially in the context of Parkinson's disease (PD). In particular, its role in immunomodulation, impact on inflammation, and participation in the gut-brain axis are under ongoing investigations. Recent studies have revealed new data that could be important for exploring the neurodegeneration mechanisms connected with the gut microbiota, potentially leading to the development of new methods of treatment. In this review, the potential roles of the gut microbiota in future disease-modifying therapies were discussed and the properties of the intestinal microbiota-including its impacts on metabolism and short-chain fatty acids and vitamins-were summarized, with a particular focus on atypical Parkinsonian syndromes. This review focused on a detailed description of the numerous mechanisms through which the microbiota influences neurodegenerative processes. This review explored potentially important connections between the gut microbiota and the evolution and progression of atypical Parkinsonian syndromes. Finally, a description of recently derived results regarding the microbiota alterations in atypical Parkinsonian syndromes in comparison with results previously described in PD was also included.

Indexed as

Gastrointestinal MicrobiomeParkinsonian DisordersAnimalsHumansParkinson Diseaseatypical Parkinsonian syndromesgut–brain axisintestinal microbiotaneurodegenerationParkinson diseaseshort-chain fatty acidssystemic inflammationtauvitamin B12α-synuclein

Identifiers

PMID40362171
PMCPMC12071724

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.